Skip to Content

Liothyronine Pregnancy and Breastfeeding Warnings

Liothyronine is also known as: Cytomel, Triostat

Liothyronine Pregnancy Warnings

Animal studies have not been reported. Thyroid hormones do not readily cross the placenta. Clinical experience to date does not indicate any adverse effects on the fetus when thyroid hormones are administered to pregnant women. There are no controlled data in human pregnancy. AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed. US FDA pregnancy category A: Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

Use is considered acceptable. AU TGA pregnancy category: A US FDA pregnancy category: A Comments: -While clinical experience to date does not provide any evidence of fetal harm, some authorities recommend weighing the possible risk of fetal congenital abnormalities against the risk of untreated maternal hypothyroidism.

See references

Liothyronine Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Yes Comments: -May interfere with neonatal screening programmes. -Liothyronine (T3) is a normal component of human milk; if replacement doses are required by the mother, it is not necessarily a reason to discontinue breastfeeding. -Dose requirements may be increased in the postpartum period compared to pre-pregnancy requirements in women with Hashimoto's thyroiditis.

Due to lack of information on the exogenous use of this drug during breastfeeding, an alternate drug may be preferred.

See references

References for pregnancy information

  1. "Product Information. Cytomel (liothyronine)." Monarch Pharmaceuticals Inc, Bristol, TN.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Triostat (liothyronine)." JHP Pharmaceuticals, Saddle River, NJ.

References for breastfeeding information

  1. "Product Information. Triostat (liothyronine)." JHP Pharmaceuticals, Saddle River, NJ.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  3. "Product Information. Cytomel (liothyronine)." Monarch Pharmaceuticals Inc, Bristol, TN.
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  5. Cerner Multum, Inc. "Australian Product Information." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.